Use Of Non-Inferiority Trials Could Increase Despite Unclear Guidance
Regulators need to provide greater clarity on non-inferiority clinical trial designs, an Amgen exec said during FDA's 2006 Science Forum
You may also be interested in...
FDA will generally take a case-by-case approach to considering and accepting development programs using clinical trial designs discussed in its Critical Path opportunities list
FDA's biomarker qualification guidance will establish a "fitness for use" standard for marker validation, Deputy Commissioner for Operations Janet Woodcock said
Progression-free survival will have to be validated as a surrogate for survival on a cancer-by-cancer basis for PFS to be considered as a valid endpoint for approval, comments by FDA and members of its Oncologic Drugs Advisory Committee suggest